A Double-Blind, Active-Controlled, Multiple-Ascending Dose Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomonas aeru

Sponsored by Respirion Pharmaceuticals Pty Ltd (Australia)